Novel Therapeutics in Acute Myeloid Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting DiNardo, C. D., Stone, R. M., Medeiros, B. C. 2017: 495–503

Abstract

In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

View details for DOI 10.1200/EDBK_175401

View details for PubMedID 30372205